NO20055631L - Doseringsform inneholdende pantoprazol som aktiv ingrediens - Google Patents

Doseringsform inneholdende pantoprazol som aktiv ingrediens

Info

Publication number
NO20055631L
NO20055631L NO20055631A NO20055631A NO20055631L NO 20055631 L NO20055631 L NO 20055631L NO 20055631 A NO20055631 A NO 20055631A NO 20055631 A NO20055631 A NO 20055631A NO 20055631 L NO20055631 L NO 20055631L
Authority
NO
Norway
Prior art keywords
active ingredient
dosage form
form containing
containing pantoprazole
pantoprazole
Prior art date
Application number
NO20055631A
Other languages
English (en)
Other versions
NO337921B1 (no
Inventor
Rango Dietrich
Hartmut Ney
Isabel Anstett-Klein
Marc Schiller
Manfred Hartmann
Sabine Schafer-Preuss
Original Assignee
Takeda Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33436112&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20055631(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Gmbh filed Critical Takeda Gmbh
Publication of NO20055631L publication Critical patent/NO20055631L/no
Publication of NO337921B1 publication Critical patent/NO337921B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Doseringsformer for oral administrasjon av magnesiumsaltet av pantoprazol er beskrevet.
NO20055631A 2003-05-08 2005-11-29 Doseringsform inneholdende pantoprazol som aktiv ingrediens NO337921B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03010328 2003-05-08
EP04001754 2004-01-28
PCT/EP2004/050729 WO2004098594A2 (en) 2003-05-08 2004-05-07 Dosage form containing pantoprazole as active ingredient

Publications (2)

Publication Number Publication Date
NO20055631L true NO20055631L (no) 2005-11-29
NO337921B1 NO337921B1 (no) 2016-07-11

Family

ID=33436112

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055631A NO337921B1 (no) 2003-05-08 2005-11-29 Doseringsform inneholdende pantoprazol som aktiv ingrediens

Country Status (27)

Country Link
US (2) US20060240100A1 (no)
EP (2) EP1624869B1 (no)
JP (2) JP4878284B2 (no)
KR (2) KR20110104124A (no)
AR (1) AR044264A1 (no)
AU (2) AU2004237363B2 (no)
BR (2) BRPI0410044B8 (no)
CA (1) CA2489140C (no)
CL (1) CL2004000983A1 (no)
CY (2) CY1113128T1 (no)
DK (2) DK2316454T3 (no)
EA (2) EA016824B1 (no)
ES (2) ES2396197T3 (no)
HK (1) HK1090546A1 (no)
HR (2) HRP20120754T1 (no)
IL (2) IL171365A (no)
MX (1) MXPA05000411A (no)
NO (1) NO337921B1 (no)
NZ (1) NZ543181A (no)
PE (1) PE20050199A1 (no)
PL (2) PL2316454T3 (no)
PT (2) PT2316454E (no)
RS (1) RS53443B (no)
SI (2) SI2316454T1 (no)
TW (1) TW200509992A (no)
WO (1) WO2004098594A2 (no)
ZA (1) ZA200508202B (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20050150A1 (es) 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
AU2005239838B2 (en) 2004-05-07 2011-08-11 Takeda Gmbh Pharmaceutical dosage form comprising pellets as well as its manufacturing process
AR054358A1 (es) * 2005-05-13 2007-06-20 Combino Pharm Sl Formulaciones que contienen pantoprazol libre de acido y sus sales
EP1747776A1 (en) * 2005-07-29 2007-01-31 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising granular pantoprazole
TWI519322B (zh) * 2008-04-15 2016-02-01 愛戴爾製藥股份有限公司 包含弱鹼性藥物及控制釋放劑型之組合物
WO2010018593A2 (en) * 2008-07-03 2010-02-18 Torrent Pharmaceuticals Ltd. Gastric acid resistant benzimidazole multiple unit tablet composition
MX2013000827A (es) * 2010-07-22 2013-06-28 Lupin Ltd Composicion de tableta de unidad multiple.
KR101787481B1 (ko) 2010-10-21 2017-10-18 롯데정밀화학 주식회사 장용성 경질 캡슐용 조성물 및 상기 조성물을 사용하여 제조된 장용성 경질 캡슐
ITMI20111168A1 (it) * 2011-06-27 2012-12-28 Professional Dietetics Srl Composizioni farmaceutiche comprendenti idrossipropilmetilcellulosa e/o acido ialuronico e loro uso
WO2014016754A2 (en) * 2012-07-26 2014-01-30 Lupin Limited Pharmaceutical compositions of proton pump inhibitor
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
EP3522889A4 (en) * 2016-10-06 2020-05-27 Jubilant Generics Limited PHARMACEUTICAL COMPOSITION OF PANTOPRAZOLE WITH DELAYED RELEASE AND METHOD FOR THE PRODUCTION THEREOF
WO2023214016A1 (en) * 2022-05-06 2023-11-09 Evonik Operations Gmbh Dosage form with drug release at ph 3 to 6 using double coating system with at least one release acceleration agent

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
IL75400A (en) 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
FI90544C (fi) 1986-11-13 1994-02-25 Eisai Co Ltd Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi
US5026560A (en) 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
IL85472A (en) 1987-03-09 1991-06-30 Procter & Gamble Pharmaceutical compositions for treating gastrointestinal disorders
JPH0768125B2 (ja) 1988-05-18 1995-07-26 エーザイ株式会社 酸不安定化合物の内服用製剤
DE3901151A1 (de) 1989-01-17 1990-07-19 Hoechst Ag Stabile pharmazeutische zubereitungen von thienoimidazol-derivaten und deren orale anwendung als magensaeuresekretionshemmer
CA2050067C (en) * 1990-08-30 2000-05-30 Yasushi Morita Controlled drug release composition
YU48263B (sh) * 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
AU671811B2 (en) * 1991-12-18 1996-09-12 Warner-Lambert Company A process for the preparation of a solid dispersion
CA2161256C (en) * 1993-04-27 2004-06-29 Nancy M. Gray Methods and compositions for treating gastric disorders using optically pure (-) pantoprazole
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
CA2170647C (en) 1994-07-08 2001-03-13 Pontus John Arvid Bergstrand Multiple unit tableted dosage form i
US6132768A (en) * 1995-07-05 2000-10-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors
US5945124A (en) 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
SE512835C2 (sv) * 1996-01-08 2000-05-22 Astrazeneca Ab Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
SE9600070D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE508669C2 (sv) 1996-04-26 1998-10-26 Astra Ab Nytt förfarande
JP3249914B2 (ja) * 1996-06-04 2002-01-28 清水食品株式会社 成型用焼結金型およびその形成方法
EP0866084A3 (en) * 1997-03-21 2002-02-27 Mitsui Chemicals, Inc. Production process of cross-linked polyaspartic acid resin
WO1999027917A1 (de) * 1997-11-28 1999-06-10 Byk Gulden Lomberg Chemische Fabrik Gmbh Arzneimittelzubereitung in tabletten- oder pelletform für säurelabile wirkstoffe
SI1037607T1 (en) 1997-12-08 2004-08-31 Altana Pharma Ag Novel suppository form comprising an acid-labile active compound
SE9704869D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
HU228772B1 (en) * 1998-05-15 2013-05-28 Warner Lambert Co Gamma-aminobutyric acid derivatives containing, solid compositions and process for preparing the same
ZA9810765B (en) * 1998-05-28 1999-08-06 Ranbaxy Lab Ltd Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.
JP3274416B2 (ja) * 1998-05-29 2002-04-15 佐藤製薬株式会社 口腔内崩壊性粒状製剤
CA2507743C (en) 1998-08-12 2008-03-18 Altana Pharma Ag Oral administration form for pyridin-2-ylmethylsulfinyl-1h-benzimidazoles
DE19843413C1 (de) * 1998-08-18 2000-03-30 Byk Gulden Lomberg Chem Fab Neue Salzform von Pantoprazol
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
WO2000074654A1 (en) 1999-06-07 2000-12-14 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel preparation and administration form comprising an acid-labile active compound
US6420473B1 (en) * 2000-02-10 2002-07-16 Bpsi Holdings, Inc. Acrylic enteric coating compositions
US6346269B1 (en) * 2000-05-08 2002-02-12 Standard Chem. & Pharm. Co., Ltd. Method for preparing an oral formulation containing acid-sensitive drugs and oral formulation made thereby
SI20720A (sl) * 2000-11-20 2002-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Nov farmacevtski pripravek v obliki celuloznih kapsul uporaben za derivate benzimidazola
MY137726A (en) * 2000-11-22 2009-03-31 Nycomed Gmbh Freeze-dried pantoprazole preparation and pantoprazole injection
CA2430824C (en) * 2000-12-07 2012-05-08 Altana Pharma Ag Pharmaceutical preparation in the form of a suspension comprising an acid-labile active ingredient
ATE541564T1 (de) 2000-12-07 2012-02-15 Nycomed Gmbh Schnell zerfallende tablette mit einem säurelabilen wirkstoff
MY140561A (en) * 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
PE20050150A1 (es) 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
AU2005239838B2 (en) 2004-05-07 2011-08-11 Takeda Gmbh Pharmaceutical dosage form comprising pellets as well as its manufacturing process
JP4563077B2 (ja) * 2004-05-28 2010-10-13 株式会社ロッテ キャンディ及びその製造方法

Also Published As

Publication number Publication date
PT2316454E (pt) 2012-12-06
PL1624869T3 (pl) 2012-11-30
CY1113462T1 (el) 2016-06-22
EP2316454B1 (en) 2012-09-26
KR101237742B1 (ko) 2013-02-26
WO2004098594A2 (en) 2004-11-18
AU2010200905A1 (en) 2010-04-01
IL229510A (en) 2016-09-29
EA201101119A1 (ru) 2011-12-30
BRPI0410044B8 (pt) 2021-05-25
DK2316454T3 (da) 2013-01-21
ZA200508202B (en) 2006-12-27
CA2489140C (en) 2006-10-17
BRPI0410044A (pt) 2006-04-25
US20090208571A1 (en) 2009-08-20
ES2390342T3 (es) 2012-11-12
EA027734B1 (ru) 2017-08-31
PE20050199A1 (es) 2005-03-26
KR20110104124A (ko) 2011-09-21
AU2004237363B2 (en) 2009-12-10
CA2489140A1 (en) 2004-11-18
US20060240100A1 (en) 2006-10-26
NZ543181A (en) 2009-10-30
JP4878284B2 (ja) 2012-02-15
AU2010200905B2 (en) 2012-04-05
ES2396197T3 (es) 2013-02-19
AU2004237363A1 (en) 2004-11-18
BR122016006880B8 (pt) 2021-05-25
MXPA05000411A (es) 2005-03-23
US8703192B2 (en) 2014-04-22
AR044264A1 (es) 2005-09-07
RS20050818A (en) 2008-04-04
PL2316454T3 (pl) 2013-03-29
BRPI0410044B1 (pt) 2019-05-07
TW200509992A (en) 2005-03-16
SI1624869T1 (sl) 2012-10-30
WO2004098594A3 (en) 2004-12-09
HRP20121005T1 (hr) 2013-01-31
HRP20120754T1 (hr) 2012-11-30
IL229510A0 (en) 2013-12-31
KR20060010774A (ko) 2006-02-02
BR122016006880B1 (pt) 2020-11-10
DK1624869T3 (da) 2012-10-01
EP1624869A2 (en) 2006-02-15
SI2316454T1 (sl) 2013-01-31
IL171365A (en) 2014-08-31
PT1624869E (pt) 2012-09-18
CL2004000983A1 (es) 2005-03-04
JP2011126912A (ja) 2011-06-30
NO337921B1 (no) 2016-07-11
HK1090546A1 (en) 2006-12-29
EP2316454A1 (en) 2011-05-04
EP1624869B1 (en) 2012-07-04
EA016824B1 (ru) 2012-07-30
EP2316454B9 (en) 2013-01-02
EA200501697A1 (ru) 2006-06-30
CY1113128T1 (el) 2016-04-13
JP2006525286A (ja) 2006-11-09
JP5162689B2 (ja) 2013-03-13
RS53443B (en) 2014-12-31

Similar Documents

Publication Publication Date Title
NO20055631L (no) Doseringsform inneholdende pantoprazol som aktiv ingrediens
CO5590918A2 (es) Formulaciones
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
NO20043702L (no) 8-azaprostaglandinderivatforbindelser og legemidler inneholdende forbindelsene som den aktive bestanddel
CY1118179T1 (el) Φαρμακευτικη συνθεση
NO20064041L (no) Substituerte pyrazolin sammensetninger, deres fremstilling og anvendelse som medikamenter
CY1109962T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4,5]δεκαν-2-ονης για τη θεραπεια παχυσαρκιας
NO20080220L (no) Formuleringer med hoy medikament belastning og doseringsformer
ATE410424T1 (de) Spirocyclische cyclohexan-derivate
TW200517106A (en) Sustained release pharmaceutical compositions
CY1109366T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4.5]δεκαν-2-ονης
TNSN06012A1 (en) Emulsifying systems containing azetidine derivatives
EA200601901A1 (ru) Композиции, содержащие иммуномодулирующие соединения для лечения и управления течением миелодиспластических синдромов и способы с их использованием
TW200503785A (en) Dosage form containing (S)-pantoprazole as active ingredient
NO20054360L (no) Nye oxazolderivater, deres fremstilling og anvendelse som farmasotiske preparater
DK1666473T3 (da) Carboxylsyreforbindelser og medicinske sammensætninger indeholdende samme som aktiv ingrediens
EA200601015A1 (ru) Пероральные композиции дезоксипеганина и их применение
NO20044900L (no) Progestagene doseringsenheter
NO20054319L (no) Neovaskulaseringspromoter
TW200616951A (en) Indole derivatives, their manufacture and use as pharmaceutial agents
NO20080947L (no) Terapeutisk middel for hypertensjon

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: PLOUGMANN & VINGTOFT, POSTBOKS 1003 SENTRUM, 0104

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: TAKEDA GMBH, DE

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: TAKEDA GMBH, DE

MM1K Lapsed by not paying the annual fees